Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fosifloxuridine nafalbenamide - Nucana BioMed

Next Previous
Search
Drug Profile

Fosifloxuridine nafalbenamide - Nucana BioMed

Alternative Names: 5-Fluorouracil ProTide - NuCana; FUDR-phosphoramidate; NUC 3373

Latest Information Update: 03 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cardiff University
  • Developer NuCana
  • Class Amino acids; Antineoplastics; Fluorinated hydrocarbons; Naphthalenes; Pyrimidine nucleotides; Small molecules; Uracil nucleotides
  • Mechanism of Action DNA synthesis inhibitors; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer
  • Phase I/II Solid tumours
  • Phase I Non-small cell lung cancer
  • No development reported Breast cancer

Most Recent Events

  • 11 Nov 2024 Efficacy and adverse events data from the phase Ib/II trial in Solid tumours released by Nucana
  • 29 Aug 2024 Nucana terminates a phase II NuTide:323 trial in Colorectal cancer in USA, France, Germany, Italy, Spain and United Kingdom based on the Steering Committee's recommendation as study was unlikely to achieve its primary objective of demonstrating superior progression-free survival as per pre-planned initial analysis (NCT05678257)
  • 21 Mar 2024 NuCana BioMed completes a phase I/II trial in Colorectal cancer (Combination therapy, Metastatic disease, Recurrent, Second-line therapy or greater, Inoperable/Unresectable) in United Kingdom, USA and France (IV) (NCT03428958)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top